The Company’s primary focus is its degenerative eye disease platform, supported by a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). Its initial human therapeutic candidate is a metformin-based topical ophthalmic formulation intended for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). A first-in-human clinical trial ... The Company’s primary focus is its degenerative eye disease platform, supported by a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). Its initial human therapeutic candidate is a metformin-based topical ophthalmic formulation intended for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). A first-in-human clinical trial is targeted under a Cooperative Research and Development Agreement (CRADA) with the NEI. Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study Palm Beach Gardens, FL, April 15, 2026 (GLOBE... Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study · Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation. As previously disclosed, the Company is developing a metformin-based topical ophthalmic formulation intended for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). The Company is also advancing development of a K9 therapeutic candidate targeting PDE6-associated retinal degeneration, a genetic early-onset retinal disease in dogs that may provide translational insights relevant to human Retinitis Pigmentosa.

Original title: “Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy”

The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.

Original title: “Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data”

The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis despite the drug’s loss to Sanofi’s Avapro in a Phase 3 study.

Original title: “Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease”

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall response rate in a Phase 2 trial.

Original title: “BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial”

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” profile, the company said.

Original title: “Spyre drug for inflammatory bowel disease shows promise in early study”

The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a tough-to-treat tumor.

Original title: “Revolution pancreatic cancer drug nearly doubles survival in key trial”

Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.

Original title: “Allogene stock sails after CAR T clears residual lymphoma in early data cut”

In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory filings.

Original title: “Revolution rises 40% as pancreatic cancer drug doubles survival”

Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC inhibitor.

Original title: “IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy”

Company expects two‑year dfs data by q1 2028

Original title: “Transgene completes randomisation in phase 2 trial of tg4050”

New authorisation offers additional option for patients with lvef ≥40%

Original title: “Bayer wins MHRA approval for Kerendia in heart failure”

The FDA in a complete response letter to Replimune maintained its original objection to the single-arm trial the biotech used to support the application for RP1.

Original title: “Replimune’s advanced melanoma drug rebuffed by FDA for second time”